Lipigon Pharmaceuticals AB (publ)

DB:9RP Stock Report

Market Cap: €2.2m

Lipigon Pharmaceuticals Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Stefan Nilsson

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure9.1yrs
CEO ownership1.8%
Management average tenureno data
Board average tenure3.4yrs

Recent management updates

Recent updates

CEO

Stefan Nilsson (45 yo)

9.1yrs

Tenure

Dr. Stefan K. Nilsson serves as the Chief Executive Officer of Lipigon Pharmaceuticals AB since 2016. Dr. Nilsson is an entrepreneur and Co-Founder of Lipigon. Dr. Nilsson has been central in all Lipigon’s...

Board Members

NamePositionTenureCompensationOwnership
Lars Öhman
Business Development Manager & Chairman13.1yrsno data0.23%
€ 5.1k
Fredrik Lindgren
Director1.1yrsno datano data
Jessica Martinsson
Independent Director3.8yrsno data0.11%
€ 2.4k
David Westberg
Independent Director2.1yrsno data0.020%
€ 442.8
Johannes Hulthe
Director4.1yrsno data0.13%
€ 3.0k
Maj Hedtjarn
Scientific Advisorno datano datano data
Ludger Scheja
Scientific Advisorno datano datano data
Sander Kersten
Scientific Advisorno datano datano data
Troels Koch
Scientific Advisorno datano datano data
Jorg Heeren
Scientific Advisorno datano datano data
Eva Lindqvist
Independent Director3.1yrsno data0.61%
€ 13.3k

3.4yrs

Average Tenure

57.5yo

Average Age

Experienced Board: 9RP's board of directors are considered experienced (3.4 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/02 09:21
End of Day Share Price 2025/01/31 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Lipigon Pharmaceuticals AB (publ) is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Carl RamaniusRedeye